Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL HL Update 2021 | Emerging concepts in Hodgkin lymphoma

Dennis Eichenauer • 15 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin

Dennis Eichenauer, MD, University Hospital of Cologne, Cologne, Germany, outlines novel approaches in Hodgkin lymphoma, including the use of anti-PD-1 antibodies in the first-line, as well as anti-CD25 directed approaches as discussed at the virtual Update on Hodgkin Lymphoma organized by the International Symposium on Hodgkin Lymphoma (ISHL). This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Dennis Eichenauer

3:17
Nodular lymphocyte-predominant Hodgkin lymphoma
Dennis Eichenauer • 15 Mar 2021
1:06
NHL following treatment for classical HL
Dennis Eichenauer • 15 Mar 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals